

# Review of: "'4-Aminoquinazoline-6, 7-diol' derivatives for enhanced EGFR binding (as inhibitor) against Lung cancer"

Pravin Wakte

**Potential competing interests:** The author(s) declared that no potential competing interests exist.

I have gone through the manuscript '4-Aminoquinazoline-6, 7-diol' derivatives for enhanced EGFR binding (as inhibitor) against Lung cancer.'

1. The author should revise the manuscript to decrease the grammatical errors.
2. The author hasn't mentioned any synthetic protocol for the compounds. On the basis of in silico cytotoxic assay, I can't evaluate the potency of compounds. The compounds must be synthesized, characterized and biologically evaluated.
3. The author has only targeted non-mutated cell lines and wild-type protein for lung cancer. However, it must be noted that, lung cancer has lot of mutations and the novel compounds must be designed taking into account the L858R/T790M as well as C797S mutations to start with.